© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Biomarkers in the cerebrospinal fluid and blood could hold the key to early diagnosis of Alzheimer disease, featuring insight from Rebecca M. Edelmayer, PhD, director of scientific engagement at the Alzheimer’s Association.
Fred Lublin, MD; Wallace Brownlee, MBChB, PhD, FRACP; Patricia K. Coyle, MD; and Sven Meuth, MD, PhD, discuss their approach to first-line therapy and the primary therapies they use based on approval status in the United States and Europe.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Bryan Davis, PsyD, MS, clinical health psychology fellow, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic.
Fintepla, marketed by Zogenix, will be available for prescription for the rare pediatric epilepsy syndrome beginning in July 2020 through a REMS program.
In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.
Evusheld Increased Attenuated SARS-CoV-2 Antibodies From MS B-Cell Depleting Medications
NeurologyLive® Friday 5 — June 24, 2022
Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD
FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns